CA
NZ
UK
AU
IND
US
Allarity Therapeutics, Inc. (NASDAQ:ALLR) filed a Form 8-K that attaches a press release dated September 28, 2026, announcing that it has expanded its in-house laboratory in Tarpon Springs, Florida to include proteomics and cell line research.
Alzamend Neuro, Inc. (NASDAQ:ALZN) furnished a Form 8-K on September 29, 2026 attaching presentation slides given the same day by the principal investigator of its Phase 1/2A clinical trial. The filing says Dr. Ovidiu C.
AngioDynamics Inc (NASDAQ:ANGO) filed two amendments to its Annual Report on Form 10-K for the fiscal year ended May 31, 2026 on September 29, 2026. Amendment No. 1, accession 0001140361-26-037943, adds the Part III information.
argenx SE (NASDAQ:ARGX) furnished a Form 6-K on September 29, 2026 attaching a press release announcing new data from its portfolio at two neuromuscular meetings held in Orlando, Florida: the annual meeting of the American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) and the …
Ascendis Pharma A/S (NASDAQ:ASND) reported in a Form 6-K dated September 29, 2026 that it has registered an increase in its share capital of nominal DKK 210,812 following the exercise of warrants, resulting in 210,812 new ordinary shares. The increase raises the company's share …
Cytek Biosciences, Inc. (NASDAQ:CTKB) filed a Form 8-K reporting that itsBoard of Directorsadopted amended and restated bylaws on September 23, 2026. The report was made under Item 5.03, the item of Form 8-K that covers amendments to a company's articles of incorporation or bylaws.
Citius Oncology, Inc. (NASDAQ:CTOR) filed a Form 8-K reporting the results of its annual meeting of stockholders, held on September 29, 2026. The filing, made under Item 5.07 (Submission of Matters to a Vote of Security Holders), shows that holders elected three Class II …
Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) filed a Form 8-K reporting the results of its annual meeting of stockholders, held on September 24, 2026 at 822 A1A North, Suite 306, in Ponte Vedra, Florida. Stockholders re-elected a director, ratified the company's auditor, approved an increase in …
● A New Drug Application for ORPATHYS (savolitinib) plus TAGRISSO (osimertinib) has been submitted to the FDA by AstraZeneca.
● Heron received an exclusive, sublicensable US license from Long Grove Pharmaceuticals to import, distribute, sell and market certain products.
Please wait processing your request...